Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

THEMIS MEDICARE 2023-24 Annual Report Analysis
Thu, 27 Jun

THEMIS MEDICARE has announced its results for the year ended March 2024. Let us have a look at the detailed performance review of the company during FY23-24.

THEMIS MEDICARE Income Statement Analysis

  • Operating income during the year rose 7.7% on a year-on-year (YoY) basis.
  • The company's operating profit decreased by 13.3% YoY during the fiscal. Operating profit margins witnessed a fall and stood at 18.4% in FY24 as against 22.9% in FY23.
  • Depreciation charges increased by 16.7% and finance costs decreased by 2.0% YoY, respectively.
  • Other income declined by 58.7% YoY.
  • Net profit for the year declined by 23.5% YoY.
  • Net profit margins during the year declined from 16.1% in FY23 to 11.4% in FY24.

THEMIS MEDICARE Income Statement 2023-24

No. of Mths Year Ending 12 Mar-23* 12 Mar-24* % Change
Net Sales Rs m 3,543 3,818 7.7%
Other income Rs m 115 48 -58.7%
Total Revenues Rs m 3,658 3,865 5.7%
Gross profit Rs m 811 703 -13.3%
Depreciation Rs m 105 122 16.7%
Interest Rs m 96 94 -2.0%
Profit before tax Rs m 725 534 -26.3%
Tax Rs m 156 99 -36.5%
Profit after tax Rs m 569 435 -23.5%
Gross profit margin % 22.9 18.4
Effective tax rate % 21.5 18.6
Net profit margin % 16.1 11.4
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Must See: These Segments are Witnessing Incredible Growth with Modi's Push

THEMIS MEDICARE Balance Sheet Analysis

  • The company's current liabilities during FY24 stood at Rs 2 billion as compared to Rs 1 billion in FY23, thereby witnessing an increase of 9.7%.
  • Long-term debt down at Rs 268 million as compared to Rs 284 million during FY23, a fall of 5.9%.
  • Current assets rose 10% and stood at Rs 3 billion, while fixed assets rose 10% and stood at Rs 3 billion in FY24.
  • Overall, the total assets and liabilities for FY24 stood at Rs 6 billion as against Rs 5 billion during FY23, thereby witnessing a growth of 10%.

THEMIS MEDICARE Balance Sheet as on March 2024

No. of Mths Year Ending 12 Mar-23* 12 Mar-24* % Change
Networth Rs m 3,394 3,777 11.3
 
Current Liabilities Rs m 1,494 1,639 9.7
Long-term Debt Rs m 284 268 -5.9
Total Liabilities Rs m 5,242 5,757 9.8
 
Current assets Rs m 2,748 3,025 10.1
Fixed Assets Rs m 2,494 2,732 9.6
Total Assets Rs m 5,242 5,757 9.8
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



THEMIS MEDICARE Cash Flow Statement Analysis

  • THEMIS MEDICARE's cash flow from operating activities (CFO) during FY24 stood at Rs 221 million, an improvement of 37.3% on a YoY basis.
  • Cash flow from investing activities (CFI) during FY24 stood at Rs -159 million on a YoY basis.
  • Cash flow from financial activities (CFF) during FY24 stood at Rs -88 million on a YoY basis.
  • Overall, net cash flows for the company during FY24 stood at Rs -26 million from the Rs -77 million net cash flows seen during FY23.

THEMIS MEDICARE Cash Flow Statement 2023-24

Particulars No. of months 12 12 % Change
Year Ending Mar-23 Mar-24
Cash Flow from Operating Activities Rs m 161 221 37.3%
Cash Flow from Investing Activities Rs m -240 -159 -
Cash Flow from Financing Activities Rs m 1 -88 -
Net Cash Flow Rs m -77 -26 -
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Current Valuations for THEMIS MEDICARE

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 4.7, an decline from the EPS of Rs 61.8 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 214.7, stands at 79.9 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 5.2 times, while the price to sales ratio stands at 5.2 times.
  • The company's price to cash flow (P/CF) ratio stood at 175.2 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-23* 12 Mar-24*
Sales per share (Unadj.) Rs 385.1 41.5
TTM Earnings per share Rs 61.8 4.7
Diluted earnings per share Rs 6.2 4.7
Price to Cash Flow x 159.3 175.2
TTM P/E ratio x 248.0 79.9
Price / Book Value ratio x 2.9 25.9
Market Cap Rs m 9,784 97,726
Dividends per share (Unadj.) Rs 0.5 0.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Ratio Analysis for THEMIS MEDICARE

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 1.8x during FY24, from 1.8x during FY23. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 6.7x during FY24, from 8.6x during FY23. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company declined and down at 11.5% during FY24, from 16.8% during FY24. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company declined and down at 15.5% during FY24, from 22.3% during FY23. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company declined and down at 9.2% during FY24, from 12.7% during FY23. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-23* 12 Mar-24*
Current ratio x 1.8 1.8
Debtors’ Days Days 1,494 1,701
Interest coverage x 8.6 6.7
Debt to equity ratio x 0.1 0.1
Return on assets % 12.7 9.2
Return on equity % 16.8 11.5
Return on capital employed % 22.3 15.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



To see how THEMIS MEDICARE has performed over the last 5 years, please visit here.

THEMIS MEDICARE Share Price Performance

Over the last one year, THEMIS MEDICARE share price has moved down from Rs 1,352.2 to Rs 0.0, registering a loss of Rs 1,352.2 or around 100.0%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 36,790.6 (up 0.3%). Over the last one year it has moved up from 25,406.2 to 36,790.6, a gain of 11,384 points (up 44.8%).

Overall, the NIFTY 50 is down 0.0% over the year.

(To know more, check out historical annual results for THEMIS MEDICARE and quarterly results for THEMIS MEDICARE)

Annual Report FAQs

What is the current share price of THEMIS MEDICARE?

THEMIS MEDICARE currently trades at Rs 289.5 per share. You can check out the latest share price performance of THEMIS MEDICARE here...

What was the revenue of THEMIS MEDICARE in FY24? How does it compare to earlier years?

The revenues of THEMIS MEDICARE stood at Rs 3,865 m in FY24, which was up 5.7% compared to Rs 3,658 m reported in FY23.

THEMIS MEDICARE's revenue has grown from Rs 2,051 m in FY20 to Rs 3,865 m in FY24.

Over the past 5 years, the revenue of THEMIS MEDICARE has grown at a CAGR of 17.2%.

What was the net profit of THEMIS MEDICARE in FY24? How does it compare to earlier years?

The net profit of THEMIS MEDICARE stood at Rs 435 m in FY24, which was down -23.5% compared to Rs 569 m reported in FY23.

This compares to a net profit of Rs 729 m in FY22 and a net profit of Rs 262 m in FY21.

Over the past 5 years, THEMIS MEDICARE net profit has grown at a CAGR of 28.7%.

What does the cash flow statement of THEMIS MEDICARE reveal?

The cash flow statement is the financial statement that presents the cash inflows and outflows of a company during a given period of time.

This statement is one of the most useful tools for judging a company's liquidity position. The ratios and parameters in this statement helps test a company's financial health.

The cash flow statement of THEMIS MEDICARE reveals:

  • Cash flow from operations increased in FY24 and stood at Rs 221 m as compared to Rs 161 m in FY23.
  • Cash flow from investments increased in FY24 and stood at Rs -159 m as compared to Rs -240 m in FY23.
  • Cash flow from financial activity decreased in FY24 and stood at Rs -88 m as compared to Rs 1 m in FY23.

Here's the cash flow statement of THEMIS MEDICARE for the past 5 years.

(Rs m)FY20FY21FY22FY23FY24
From Operations3570344161221
From Investments-55-157-156-240-159
From Financial Activity67-256-1751-88
Net Cashflow1615713-77-26

What does the Key Ratio analysis of THEMIS MEDICARE reveal?

Be it the company's profitability, operations effectiveness or utilization of funds, ratio analysis is an important tool which helps in making investment decisions.

The ratio/financial analysis of THEMIS MEDICARE reveals:

  • Operating profit margins witnessed a fall and stood at 18.4% in FY24 as against 22.9% in FY23.
  • Net profit margins declined from 16.1% in FY23 to 11.4% in FY24.
  • Debt to Equity ratio for FY24 stood at 0.1 as compared to 0.1 in FY23.

Here's the ratio/financial analysis of THEMIS MEDICARE for the past 5 years.

 FY20FY21FY22FY23FY24
Operating Profit Margin (%)17.721.527.122.918.4
Net Profit Margin (%)7.911.418.516.111.4
Debt to Equity Ratio (x)0.10.10.10.10.1

 

Equitymaster requests your view! Post a comment on "THEMIS MEDICARE 2023-24 Annual Report Analysis". Click here!